Li Wang1, Luis E F Almeida1, Nicholas A Spornick1, Nicholas Kenyon1, Sayuri Kamimura1, Alfia Khaibullina1, Mehdi Nouraie2, Zenaide M N Quezado3,4. 1. The Sheikh Zayed Institute for Pediatric Surgical Innovation, Divisions of Anesthesiology and Perioperative Medicine, Children's National Health System, George Washington University School of Medicine and Health Sciences, 111 Michigan Avenue, Washington, DC, 20010, USA. 2. Center for Sickle Cell Disease and Department of Internal Medicine, Howard University, Washington, DC, 20001, USA. 3. The Sheikh Zayed Institute for Pediatric Surgical Innovation, Divisions of Anesthesiology and Perioperative Medicine, Children's National Health System, George Washington University School of Medicine and Health Sciences, 111 Michigan Avenue, Washington, DC, 20010, USA. zquezado@childrensnational.org. 4. Center for Neuroscience Research, Children's Research Institute, Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC, 20010, USA. zquezado@childrensnational.org.
Abstract
RATIONALE: Accumulating evidence implicates the nicotinic cholinergic system in autism spectrum disorder (ASD) pathobiology. Neuropathologic studies suggest that nicotinic acetylcholine (ACh) receptor (nAChR) subtypes are altered in brain of autistic individuals. In addition, strategies that increase ACh, the neurotransmitter for nicotinic and muscarinic receptors, appear to improve cognitive deficits in neuropsychiatric disorders and ASD. OBJECTIVE: The aim of this study is to examine the role of the nicotinic cholinergic system on social and repetitive behavior abnormalities and exploratory physical activity in a well-studied model of autism, the BTBR T(+) Itpr3 (tf) /J (BTBR) mouse. METHODS: Using a protocol known to up-regulate expression of brain nAChR subtypes, we measured behavior outcomes before and after BTBR and C57BL/6J (B6) mice were treated (4 weeks) with vehicle or nicotine (50, 100, 200, or 400 μg/ml). RESULTS: Increasing nicotine doses were associated with decreases in water intake, increases in plasma cotinine levels, and at the higher dose (400 μg/ml) with weight loss in BTBR mice. At lower (50, 100 μg/ml) but not higher (200, 400 μg/ml) doses, nicotine increased social interactions in BTBR and B6 mice and at higher, but not lower doses, it decreased repetitive behavior in BTBR. In the open-field test, nicotine at 200 and 400 μg/ml, but not 100 μg/ml compared with vehicle, decreased overall physical activity in BTBR mice. CONCLUSIONS: These findings support the hypotheses that the nicotinic cholinergic system modulates social and repetitive behaviors and may be a therapeutic target to treat behavior deficits in ASD. Further, the BTBR mouse may be valuable for investigations of the role of nAChRs in social deficits and repetitive behavior.
RATIONALE: Accumulating evidence implicates the nicotinic cholinergic system in autism spectrum disorder (ASD) pathobiology. Neuropathologic studies suggest that nicotinic acetylcholine (ACh) receptor (nAChR) subtypes are altered in brain of autistic individuals. In addition, strategies that increase ACh, the neurotransmitter for nicotinic and muscarinic receptors, appear to improve cognitive deficits in neuropsychiatric disorders and ASD. OBJECTIVE: The aim of this study is to examine the role of the nicotinic cholinergic system on social and repetitive behavior abnormalities and exploratory physical activity in a well-studied model of autism, the BTBR T(+) Itpr3 (tf) /J (BTBR) mouse. METHODS: Using a protocol known to up-regulate expression of brain nAChR subtypes, we measured behavior outcomes before and after BTBR and C57BL/6J (B6) mice were treated (4 weeks) with vehicle or nicotine (50, 100, 200, or 400 μg/ml). RESULTS: Increasing nicotine doses were associated with decreases in water intake, increases in plasma cotinine levels, and at the higher dose (400 μg/ml) with weight loss in BTBRmice. At lower (50, 100 μg/ml) but not higher (200, 400 μg/ml) doses, nicotine increased social interactions in BTBR and B6 mice and at higher, but not lower doses, it decreased repetitive behavior in BTBR. In the open-field test, nicotine at 200 and 400 μg/ml, but not 100 μg/ml compared with vehicle, decreased overall physical activity in BTBRmice. CONCLUSIONS: These findings support the hypotheses that the nicotinic cholinergic system modulates social and repetitive behaviors and may be a therapeutic target to treat behavior deficits in ASD. Further, the BTBRmouse may be valuable for investigations of the role of nAChRs in social deficits and repetitive behavior.
Entities:
Keywords:
Autism; BTBR; Nicotine; Repetitive behavior; Social behavior; nAChR
Authors: Luis E F Almeida; Edna F R Pereira; Adriana L Camara; Alfred Maelicke; Edson X Albuquerque Journal: Bioorg Med Chem Lett Date: 2004-04-19 Impact factor: 2.823
Authors: L Lewejohann; C Reinhard; A Schrewe; J Brandewiede; A Haemisch; N Görtz; M Schachner; N Sachser Journal: Genes Brain Behav Date: 2006-02 Impact factor: 3.449
Authors: Jos Prickaerts; Nick P van Goethem; Richard Chesworth; Gideon Shapiro; Frank G Boess; Christoph Methfessel; Olga A H Reneerkens; Dorothy G Flood; Dana Hilt; Maria Gawryl; Sonia Bertrand; Daniel Bertrand; Gerhard König Journal: Neuropharmacology Date: 2011-11-10 Impact factor: 5.250
Authors: Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins Journal: Neuropsychopharmacology Date: 2007-04-18 Impact factor: 7.853
Authors: Li Wang; Luis E F Almeida; Margaret Nettleton; Alfia Khaibullina; Sarah Albani; Sayuri Kamimura; Mehdi Nouraie; Zenaide M N Quezado Journal: Neuropharmacology Date: 2016-09-13 Impact factor: 5.250
Authors: Rosa Marotta; Maria C Risoleo; Giovanni Messina; Lucia Parisi; Marco Carotenuto; Luigi Vetri; Michele Roccella Journal: Brain Sci Date: 2020-03-13